| Phase 4 |
| NCT06897917 |
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients… |
Opioid-Induced Constipation |
Not Yet Recruiting |
2025-03-27 |
| Phase 3 |
| NCT07629817 |
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant… |
Esophageal Squamous Cell Carcinoma |
Recruiting |
2026-07-31 |
| NCT07057427 |
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast… |
Breast Cancer |
Recruiting |
2025-07-09 |
| NCT05063136 |
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast… |
Breast Cancer |
Recruiting |
2024-11-04 |
| NCT05495152 |
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma |
Esophageal Squamous Cell Carcinoma |
Recruiting |
2024-10-02 |
| NCT04547907 |
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early… |
Breast Cancer,HER2-positive |
Recruiting |
2024-09-20 |
| NCT04280822 |
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal… |
Esophageal Cancer |
Recruiting |
2022-10-04 |
| NCT04138212 |
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally… |
Esophageal Squamous Cell Carcinoma |
Recruiting |
2022-08-09 |
| NCT07332221 |
Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A… |
Esophageal Cancer |
Not Yet Recruiting |
2026-01-12 |
| Phase 2 |
| NCT06860529 |
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer |
HR+/HER2- Breast Cancer |
Recruiting |
2026-08-19 |
| NCT07559786 |
A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab… |
SCLC, Limited Stage |
Recruiting |
2026-07-21 |
| NCT07540533 |
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy… |
Advanced Breast Cancer |
Recruiting |
2026-04-20 |
| NCT05398861 |
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative… |
HER-2 Negative Breast Cancer |
Recruiting |
2026-04-16 |
| NCT05769010 |
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases |
Metastatic Breast Cancer |
Recruiting |
2026-04-01 |
| NCT06967103 |
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer |
Breast Cancer |
Recruiting |
2026-01-08 |
| NCT06817525 |
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC |
Triple-negative Breast Cancer |
Recruiting |
2025-12-05 |
| NCT07187908 |
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at… |
Primary/Secondary Prevention |
Recruiting |
2025-09-23 |
| NCT07100600 |
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the… |
HER2-positive Advanced Breast Cancer |
Recruiting |
2025-08-11 |
| NCT06927180 |
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC |
Breast Cancer Early Stage Breast Cancer (Stage 1-3) |
Recruiting |
2025-06-23 |
| NCT06945705 |
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for… |
NSCLC |
Recruiting |
2025-04-25 |
| NCT04737889 |
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central… |
Primary Central Nervous System Lymphoma |
Recruiting |
2025-04-23 |
| NCT05209620 |
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System… |
Central Nervous System Lymphoma |
Recruiting |
2025-04-23 |
| NCT05918328 |
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of… |
Breast Cancer |
Recruiting |
2025-03-07 |
| NCT06774222 |
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative… |
Gastric/Gastroesophageal Junction Adenocarcinoma |
Recruiting |
2025-01-14 |
| NCT06749730 |
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line… |
Unresectable Biliary Tract Carcinoma |
Recruiting |
2024-12-27 |